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Introduction
Emerging evidence indicates that the capacity of a tumour to grow
and propagate resides in a small population of tumour cells,
termed cancer stem cells or tumour-initiating cells [1]. Tumour
cancer stem cells have been identified in several solid tumours,
and although the specific markers may differ from one tumour to
another, they share the ability to growth in non-differentiating con-
ditions and to self-renew, to differentiate in tumour cell types and
to generate serially transplantable tumours [2, 3]. In breast carci-
noma, the tumour-initiating cells have been identified by Al-Hajj 
et al. [4] as a rare population of CD44
CD24
low/epithelial specific
antigen
 cells. The ability of breast tumour progenitor/stem cells
to grow in non-adherent structures called mammospheres led to
the possibility to isolate, expand in culture and characterize this
population [5]. Long-term human mammosphere cultures were
shown to be composed by undifferentiated, self-renewing tumour
cells, which could differentiate into both epithelial (luminal and
ductal) and myoepithelial cell types, expressing markers of the
mature mammary gland epithelium, in the presence of serum and
of an adhesion substrate [6, 7]. Therefore, the known differentia-
tion potential of breast cancer stem cells is toward the breast glan-
dular epithelial lineages. However, it is at present unknown
whether breast cancer stem cells may exhibit cross-lineage differ-
entiation capabilities, and in particular whether they can also dif-
ferentiate into endothelial cells.
In breast cancer, there are several reports showing the pres-
ence of dysfunctional and disorganized vessels with a defective
endothelial monolayer [8]. In addition, the possibility that tumour
cells themselves organize in microvascular channels, so-called
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Breast tumour stem cells have been reported to differentiate in the epithelial lineage but a cross-lineage potential has not been investi-
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Finally, endothelial cell clones originated from mammospheres were able, when implanted in Matrigel in SCID mice, to form after 7 days
a human vessel network and, after 3–4 weeks, an epithelial tumour suggesting that in the endothelial-differentiated cells a tumourigenic
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‘vasculogenic mimicry’ [9], has been extensively described in
inflammatory breast cancer [10]. In the present study, we aimed
to evaluate whether breast tumour stem cells may also give rise to
a progeny of endothelial differentiated cells, acquiring endothelial
markers in vitro and whether they participate to tumour vascular-
ization in vivo.
For this purpose, we generated tumour-initiating breast stem
cell clones and we evaluated whether each individual clone was
able to differentiate into both epithelial and endothelial cells. We
therefore evaluated the endothelial differentiation of breast cancer
stem cells in vivo and their involvement in tumour angiogenesis.
Finally, we studied the ability of the endothelial clones to generate
the vascular and the epithelial component of tumours in severe
combined immunodeficiency (SCID) mice.
Material and methods
Isolation and in vitro expansion of progenitor
cells from breast tumour specimens
Tumour specimens were obtained from a consenting patient according
to the Ethics Commitee of the S. Giovanni Battista Hospital of Torino,
Italy. The histologic assessment showed a lobular-infiltrating carcinoma
of the pleomorphic type expressing oestrogen receptor in about 60% of
cells. Tumour specimen was finely minced with scissors and then digest-
ed by incubation for 1 h at 37C in DMEM containing collagenase II
(Sigma Chemical Company, St. Louis, MO, USA). After washings in medi-
um plus 10% FCS (GIBCO, Grand Island, NY, USA), the cell suspension
was forced through a graded series of meshes to separate the cell com-
ponents from stroma and aggregates. After filtration through a 40-m
pore filter (Becton Dickinson, San Jose, CA, USA), single cells were plat-
ed at 1000 cells/ml in serum-free DMEM-F12 (Cambrex BioScience,
Venviers, Belgium), supplemented with 10 ng/ml basic fibroblast growth
factor (bFGF), 20 ng/ml epidermal growth factor (EGF), 5 g/ml insulin
and 0.4% bovine serum albumin (all from Sigma), as described in [6].
After 7 days, the appearance of non-adherent spherical clusters of cells,
i.e. mammospheres, was observed. Mammospheres were then collected
on the bottom of a conical tube by spontaneous precipitation (20 min. at
room temperature), in order to remove non-living cells. Subsequently,
after 2–3 days, mammospheres were collected by gentle centrifugation
(800 rpm) and disaggregated through enzymatic and mechanical dissoci-
ation using trypsin and pipetting, respectively. Recovered cells were
expanded at 1000 cells/ml in the serum-free medium described above and
the process was repeated every 7 days.
Clonal sphere formation assay
Primary mammospheres were dissociated as described above and 100
cells were plated in a 96-well culture plate to obtain a single cell/well in
200 l of growth medium; 25 l of medium per well were added every 5
days. The number of clonal mammospheres for each 96-well culture plate
was evaluated after 14 days of culture. This procedure was repeated for the
tertiary spheres.
In vitro cell differentiation
To evaluate the differentiative ability of cells in the mammospheres, mam-
mospheres clones (n  13) obtained from primary mammospheres were
expanded, dissociated and grown in the differentiative epithelial and
endothelial media. Differentiation was also tested for secondary or tertiary
single cell-derived mammospheres obtained as described above. Epithelial
differentiation was obtained plating the single cell suspension from disaggre-
gated mammospheres in the presence of RPMI plus 10% FCS, without the
addition of growth factors. Endothelial differentiation was obtained culturing
the cells in EBM medium (Cambrex Bio Science) with VEGF (10 ng/ml)
(Sigma) and 10% FCS on Endothelial Cell Attachment Factor (Sigma) [11].
Endothelial cell clones were obtained placing single cells from dissoci-
ated mammospheres in 96-well plates in endothelial medium, and the gen-
erated clones expanded thereafter.
Capillary-like structure
In vitro formation of tubular structures was studied on growth factor
reduced Matrigel (Becton Dickinson). Cells (4  10
4 cells/well) were seeded
onto Matrigel-coated wells (let to gelify at 37C for 1 hr) in RPMI contain-
ing 0.25% BSA. Cells were periodically observed with a  Nikon inverted
microscope and experimental results recorded. Image analysis was per-
formed with the MicroImage analysis system (Cast Imaging srl, Venice,
Italy), as described in [12].
In vivo angiogenic and tumourigenic potential of
mammosphere-derived cells
Cells derived from CD24
/CD44
 mammosphere clones or from
CD24
/CD44
 differentiated epithelial cells or from endothelial cells
derived from mammosphere clones (n  3 for each condition) were collect-
ed and were implanted subcutaneously into SCID mice (Charles River,
Jackson Laboratories, Bar Harbor, ME, USA) within growth-factor depleted
Matrigel basement membrane (from 100 to 1  10
5 cells). Cells were har-
vested using trypsin-EDTA, washed with PBS, counted in a microcytometer
chamber and resuspended in 150 l DMEM. Cells were chilled on ice,
added to 150 l of Matrigel at 4C and injected subcutaneously into the left
back of SCID mice via a 26-gauge needle using a 1-ml syringe. After 3–4
weeks, mice were sacrificed and tumours recovered and processed for his-
tology. For serial transplant experiments, tumours were digested in Matrigel
digesting solution (Becton Dickinson) and collagenase II and the recovered
cells processed to culture in mammosphere conditions. Mammospheres
were disaggregated and cells injected to evaluate second tumour genera-
tion. The process was repeated for tertiary tumour generation.
To evaluate angiogenesis, endothelial differentiated clones were
implanted subcutaneously into SCID mice within growth-factor depleted
Matrigel (1  10
4 cells) and Matrigel plugs recovered after 7–30 days.
Tumour microvessel density was assessed by counting intratumoural
human and mouse CD31-positive vessels in 20 magnification fields. Fifty
microscopic fields were analysed for each experimental condition.
Immunofluorescence
Cytofluorimetric analysis was performed using the following antibodies, all
FITC or PE conjugated: anti-CD44 mAb (Sigma), anti-CD24 mAbJ. Cell. Mol. Med. Vol 13, No 2, 2009
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(PharMingen, BD Biosciences, Franklin Lakes, NJ, USA), anti-CD31, anti-
CD146/Muc-18 and anti-CD105 mAbs (Dako, Copenhagen, Denmark), anti-
VEGF receptor1, anti-KDR and anti-VEGF receptor 3 mAbs (R&D System,
Minneapolis, MN, USA). Isotype-matched FITC or PE-conjugated control
mouse IgG were from Dako. Cells were incubated for 30 min. at 4C with
the appropriate Ab or with the irrelevant control in PBS containing 2% heat-
inactivated human serum. For staining of the cytoplasmic antigens, single
cells were fixed in 3.5% paraformaldehyde contained 2% of sucrose at 4C
for 10 min. and then permeabilized with HEPES Triton X-100 Buffer 0.1%
for 10 min. at 4C and incubated with anti-cytokeratin (CK)14, anti-CK18 or
anti-panCK Abs (Santa Cruz Biotecnology, Santa Cruz, CA, USA). Where
needed a second step reagent, cells were stained by the addition of conju-
gated polyclonal rabbit anti-goat immunoglobulins\FITC (Dako) or polyclon-
al goat anti-rabbit immunoglobulins\FITC (Sigma) and incubated for further
30 min. at 4C. Cells were analysed on a FACScan (Becton Dickinson). In
total, 10,000 cells were analysed in each experimental point.
For confocal microscopy analysis, indirect immunofluorescence was
performed on mammosphere-derived cells on cytospin preparation of a
single cell suspension using the non-enzymatic cell solution (Sigma). For
cells grown in adhesion, indirect immunofluorescence was performed on
cells cultured on chamber slides (Nunc, Rochester, NY, USA). Cells were
fixed in 3.5% paraformaldehyde containing 2% sucrose and, when need-
ed, permeabilized with Hepes-Triton X-100 Buffer [13]. The following anti-
bodies were used: rabbit anti-von Willebrand Factor (vWF) Ab and anti--
smooth muscle actin (-SMA) mAb (Dako), rabbit anti-pan-CK Ab, goat
anti-CK14, rabbit anti-CK18 Abs (Santa Cruz), anti-vimentin mAb (Sigma,
clone 13.2), goat anti-Oct-4 Ab (Abcam, Cambridge, UK) and rabbit anti-
nestin Ab (Chemicon, Temecula, CA, USA). Sections from cryostatic or
paraffin-embedded sample of tumours recovered from SCID mice were
stained for rabbit anti-human Class I antigen Ab (BioLegend, San Diego,
CA, USA), goat anti-mouse 	2-microglobulin Ab (Santa Cruz
Biotechnology), and anti-human CD31 mAb (Dako, clone JC70A) or rat
anti-mouse CD31 mAb (Abcam). For CD31 staining, 0.1 trypsin treatment
(15 min. at 37C) was performed for antigen retrieval. Alexa Fluor 488 or
Texas Red-conjugated anti-rabbit, anti-goat, anti-rat and anti-mouse IgG
(all from Molecular Probes, Leiden, The Netherlands) were used as sec-
ondary antibodies. Confocal microscopy analysis was performed using a
Zeiss LSM 5 Pascal model confocal microscope (Carl Zeiss Int.,
Oberkochen, Germany). Hoechst 33258 dye (Sigma) was added for
nuclear staining.
Combined fluorescence in situ hybridization
(FISH) and immunofluorescence analysis
A combined immunofluorescence and FISH staining was performed to
detect CD31 expression on human chromosome 17 positive cells [13].
FISH was performed using the Vysion kit for the detection of human chro-
mosome 17 (Vysis Inc., Downers Grove, IL, USA). SG CEP 17 DNA probe
hybridizes to the centromere (band region 17p11.1-q11.1, locus D17Z1) of
human chromosome 17. Previous experiments showed negative reaction
of mouse tissue [14]. Hybridization was performed on 5-m sections
according to the manufacturer’s guidelines. In brief, the sections were
deparaffinized, dehydrated in 100% ethanol and dried at 45–50C for 2–5
min. Slides were then subjected to protease digestion for 10–20 min. at
38C, denatured (72C for 5 min.) and hybridized (37C) with prewarmed
probes (CEP17 Spectrum Green; Vysis Inc.) overnight (16–18 hrs) in
HYBrite hybridization system (Vysis Inc.). After hybridization, the rubber
cement was removed and the slides were immersed in 2 SSC for 5–10
min. at room temperature. At this point, slides were processed for
immunofluorescence detection of CD31 protein. Slides were incubated for
60 min. at room temperature with the anti-human CD31 mAb (Dako, clone
JC70A). After a brief wash in Tris buffer, immunodetection was performed
using a Texas Red anti-mouse IgG (Molecular Probes) for 60 min. at room
temperature, washed three times in Tris buffer for 5 min. each, and rinsed
briefly in Aqua bidest. Nuclei were counterstained with Hoechst 33258 dye
(Sigma), and then slides were observed with a confocal microscope.
Immunohistochemistry
Sections from paraffin-embedded blocks of human tumours obtained in
SCID mice were collected onto poly-Llysine-coated slides and stained
using the following antibodies: rabbit anti-pan-CK, anti-mouse 	2-
microglobulin, or rabbit anti-HLA class I Ab (all from Santa Cruz
Biotechnology); mouse anti-CK AE1/AE3 mAb (clone AE1-AE3-PCK26),
and anti-oestrogen receptor mAb (clone 6F11) (both from Ventana Medical
Systems S.A., Illkirch CEDEX, France), anti-epithelial membrane antigen
(EMA) mAb (clone E29), anti-vimentin mAb (clone R9), polyclonal anti-
cErb2 Ab and polyclonal anti-epithelial growth factor receptor (EGFR) (all
from Dako). Endogenous peroxidase activity was blocked with 6% H2O2 for
8 min. at room temperature. Primary antibodies were applied to slides
overnight or for 1 hr at 4C. Horse radish peroxidase-labeled anti-rabbit or
anti-mouse Envision polymers (Dako) were incubated for 1 hr 30 min. The
reaction product was developed using 3,3-diaminobenzidine. Omission of
the primary Ab or substitution with an unrelated rabbit serum or mouse
IgG served as negative control.
Electron microscopy
Transmission electron microscopy was performed on Karnowsky’s fixed,
osmium tetraoxide post-fixed tissues, embedded in epoxy resin accord-
ing to standard procedures [15]. Ultra-thin sections were stained with
uranyl acetate and lead citrate and were examined with a Jeol JEM 1010
electron microscope.
Results
Isolation and characterization of breast cancer
stem cells
Breast cancer stem cells were generated using the protocol
described by Ponti et al. [6] from a lobular infiltrating breast car-
cinoma. Mammospheres were obtained by culturing enzimatically
dissociated single-cell suspension at 1000 cells/ml in serum-free
medium supplemented with EGF, bFGF and insulin (Fig. 1A).
Primary mammospheres, enzymatically digested after 10 days
and re-plated as single cell suspension, generated second passage
mammospheres. Cells were serially passaged using this proce-
dure and propagated in culture for 
50 passages. Moreover, the
mammospheres were cloned by limiting dilution of dissociated
cells, by plating one single cell per well into 96-well culture plates.312 © 2009 The Authors
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Fig. 1 Mammosphere generation, characterization and epithelial differentiation. Mammospheres were obtained by culture of dissociated cells from a
human breast tumour in mammosphere medium containing EGF and bFGF. (A) Representative micrograph showing the ematoxilin and eosin staining
of paraffin-embedded, formalin-fixed mammospheres. (B) Mammosphere clone formation analysis in secondary and tertiary passages. The number
of mammosphere clones/100 cells generated from single cells increased in the third passage. (C) Representative FACS analysis of mammosphere cell
clones showing the expression of CD44 and not CD24 and of VEGF receptor 1 (VEGFR1; the dark area indicates the specific Ab, the white area the
isotypic control). (D) Representative immunofluorescence expression by mammosphere cell clones of the stem cell markers Oct-4 and nestin, but not
of the differentiation markers CK14, CK18 and -SMA. (E) Serum supplementation and withdrawal of growth factors induced the expression of line-
age specific markers of the mature mammary epithelium (CK14, CK18 and -SMA) in cultured cells from mammosphere clones, with loss of the stem
cell markers Oct-4 and nestin. (F) Representative FACS analysis of epithelial differentiated cells showing the acquirement of CD24, the expression of
pan-CK and CK18 and the absence of the endothelial cell markers KDR and CD31. The dark area indicates the specific Ab, the white area the isotyp-
ic control. Original magnification: panel A: 100; panel D and E: 650. Nuclei were counterstained with Hoechst dye.J. Cell. Mol. Med. Vol 13, No 2, 2009
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Clonal, non-adherent secondary mammospheres formed, which in
turn gave rise to tertiary mammosphere clones (Fig. 1B), indicat-
ing the presence of self-renewing cells. The mammosphere clones
(n  24) were maintained in culture for 
3 months.
The cells of the mammospheres were CD44
/CD24
 and
showed absence of differentiation markers of the cell types of the
glandular epithelium as they did not express CK14, CK18 or -SMA.
Moreover, breast tumour progenitor cells expressed the stem cell
markers nestin and Oct-4, indicating that they are comparable to
other breast tumour progenitor cells described in the literature
[4–6] (Fig. 1C and D). Moreover, the cells expressed the VEGF
receptor 1 (Fig. 1C). This phenotype was maintained in all clones.
In vitro epithelial and endothelial differentiation
of mammosphere-derived CD44
/CD24
 clones
Thirteen mammosphere-derived CD44
/CD24
 clones were stud-
ied for epithelial and endothelial differentiation. When cultured in
the presence of serum without growth factor supplementation,
cells from dissociated mammosphere clones grew in adherent
conditions to the plastic and acquired markers associated to
myoepithelial cells (CK14 and -SMA) and luminal/ductal cells
(CK18) as well as the epithelial differentiation marker CD24, lack-
ing in undifferentiated cells. The observed epithelial differentiation
(96  5.4% of cells acquiring pan-CK) was associated with a
reduction of the stem cell markers nestin and Oct-4 expression
(Fig. 1E and F). The cells were negative for the endothelial mark-
ers VEGF receptor 2 (KDR) and CD31 (Fig. 1F).
The same mammosphere clones, used for the epithelial differ-
entiation, were plated in parallel in endothelial differentiating medi-
um (EBM with 10 ng/ml VEGF and 10% FCS) to evaluate their pos-
sible differentiation toward an endothelial phenotype. Cells from
mammosphere clones acquired an endothelial phenotype after 2
weeks of culture (85  3.0% of cells acquiring CD31). Cells
acquired expression of endothelial markers such as vascular
endothelial-cadherin, vWF, KDR, CD146, VEGF receptor 3, CD31
and CD105, but did not acquire CK18 (Fig. 2A) and CK14 (not
shown). All these endothelial markers were negative in undifferen-
tiated cells of mammospheres. No such a differentiative ability
was obtained using cells cultured in serum and previously differ-
entiated in epithelial-myoepithelial cells after 2 weeks of culture.
Endothelial differentiated cells also acquired the ability to organize
into capillary-like structures when plated onto Matrigel (Fig. 2B).
This ability was not shared by undifferentiated breast cancer pro-
genitors (Fig. 2B) or by cells differentiated into an epithelial phe-
notype (not shown).
Moreover, the percentage of differentiation into epithelial and
endothelial cells did not significantly vary from primary to single
cell-derived secondary and tertiary mammospheres (Fig. 3).
In addition, to avoid the possible presence of epithelial differ-
entiated/committed cells residing into mammosphere clones con-
taminating the endothelial lineages, we generated endothelial
clones from mammosphere-derived single cells cultured in
endothelial differentiating medium. The clonogenic ability was 6 
1.2%. Nine clones were characterized and were shown to express
all the endothelial markers studied. CD31 was expressed in 87 
5.1% of the cells whereas about 10% of the cells remained undif-
ferentiated. When endothelial clones were cultured in epithelial
medium (RPMI  10%FCS), reversal of the vascular phenotype
into an epithelial phenotype was obtained after culture for more
than 2 months (pan-CK positive cells: 96  3.4%, CD31 positive
cells: 0%), suggesting that this reversal is not dependent on a
switch between epithelial and vascular phenotype but rather on the
expansion of remaining undifferentiated stem cells.
In vivo tumourigenesis and 
vasculogenesis of breast stem cells
In vivo, undifferentiated CD44
/CD24
 and epithelial differentiat-
ed CD44
/CD24
 cells derived from mammospheres were
implanted subcutaneously in the left and right abdominal side of
the same SCID mouse, to comparatively evaluate their tumouri-
genic potential. As shown in Table 1, as low as 100 CD44
/
CD24
 breast cancer progenitor cells were able to generate in 4
weeks an aggressive epithelial tumour, resembling the tumour of
origin (Table 1, Fig. 4). In contrast, 100 epithelial differentiated
CD44
/CD24
 cells were unable to form tumours. For serial
tumour generation, breast cancer SC were obtained by dissocia-
tion of tumours developed in SCID mice and by culturing the cells
in mammosphere conditions. Mammospheres were then dissoci-
ated and re-injected for three serial tumour passages (n  6
tumours each passage with 100% incidence). By immunohisto-
chemistry, the tumours expressed low molecular weight CKs
(AE1/AE3), EMA and vimentin (Fig. 5A). In contrast, tumours were
negative for CK5/6, EGFR, c-Erb2 (Fig. 5A) and oestrogen recep-
tor. The human origin of the tumours was shown by the expres-
sion of the HLA class I antigen, and not the mouse beta2
microglobulin (Fig. 6A and B). We analysed whether vessels devel-
oped within the tumour may derive from the transplanted breast
tumour stem cells. By FISH analysis, we found that a small per-
centage of cells lining the tumour capillaries (hCD31 positive)
expressed the human chromosome 17 (Fig. 6C). The surrounding
murine tissue was negative for the human chromosome 17.
Moreover, we found that the majority of vessels detected around
the tumours were of murine origin as they expressed the mouse
	2 microglobulin, whereas several of the intratumour vessels
were of human origin, as detected by HLA class I and human
CD31 expression (vessel density: hCD31/HLA
: 1.32  0.26;
mCD31/	2
: 4.6  0.5) (Fig. 5B). These results suggest that at
least some of the intratumour vessels derived from the implanted
clones of breast tumour stem cells.
In vivo tumourigenesis and 
vasculogenesis of endothelial clones
We tested whether endothelial differentiated cells derived from
mammospheres (n  3) maintained the ability to generate314 © 2009 The Authors
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tumours when injected subcutaneously in Matrigel in SCID mice,
and whether they also participated to tumour vasculogenesis. In
addition, to dispel the presence of contaminating differentiated
cells, we also generated and tested clones from single endothelial
differentiated cells (n  3 clones). As shown in Table 1, the num-
ber of cells required for tumour generation was 10
4–10
5. After 
7 days, endothelial differentiated cells from mammosphere clones
gave rise to angiogenesis in Matrigel characterized by develop-
ment of a network of HLA class I positive human vessels connect-
ed with the mouse vasculature (Fig. 7A and B). At this time, only
few tumour clusters were seen. After 3 weeks, the epithelial com-
ponent expanded, generating tumours (Fig. 7C), expressing CK,
Fig. 2 Endothelial differentiation of mammosphere clones cultured in endothelial differentiating medium containing VEGF. (A) Representative micro-
graphs showing the expression of endothelial markers after 2-week culture by immunofluorescence staining of vascular endothelial (VE)-cadherin and
vWF, and representative FACS analysis (KDR, CD105, CD31, CD146, VEGF receptor 3 (VEGFR3): black area; the white area is the isotypic control)
showing the endothelial differentiation. CK18 was negative. (B) Representative micrographs showing the formation of capillary-like structures on
Matrigel by endothelial-differentiated breast tumour stem cells, but not by undifferentiated breast tumour progenitor cells. Capillary-like formation
assay was evaluated after 6 hrs. (Original magnification: panel A 650; panel B 200).J. Cell. Mol. Med. Vol 13, No 2, 2009
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Fig. 3 Endothelial and epithelial differentiation
of mammospheres and derived secondary and
tertiary clones. The percentage of cells differen-
tiated into endothelial or epithelial phenotype
was evaluated by the cytofluorimetric expres-
sion of CD31 (black columns) or pan-CK (white
columns), respectively. Data are the mean /
S.D. of 4 experiments.
Fig. 4 Morphological appearance of tumours derived from mammospheres. Representative micrographs showing the morphological appearance of
a tumour originated from 102 cells from mammospheres (A), resembling the original lobular breast carcinoma (B). Original magnification: 100.
Tumours were generated in SCID mice by subcutaneous injection of cells derived from CD24
/CD44
 mammosphere clones or from CD24
/CD44

differentiated epithelial cells or from endothelial cells derived from mammosphere clones (n  3 different lines for each condition), at different cell
numbers. After 4 weeks, mice were sacrificed and tumours recovered and processed for histology. For serial transplant experiments, 10
2 cells from
mammospheres obtained from primary tumours were re-injected to evaluate second tumour generation and the same procedure was applied for third
tumour generation. Moreover, endothelial differentiated clones (n  3 different clones) were implanted subcutaneously into SCID mice within growth-
factor depleted Matrigel (1  10
4 cells) and tumours recovered after 4 weeks. ND  not done.
10
2 cells 10
4 cells 10
5 cells
1
st pass 2
nd pass 3
rd pass
CD24
/CD44
 stem cells 5/5 6/6 6/6 6/6 6/6
CD24
/CD44
 epithelial differentiated cells 0/5 ND ND 4/6 6/6
Endothelial differentiated cells 0/5 ND ND 4/5 6/6
Endothelial differentiated cell clones 0/8 ND ND 8/8 ND
Table 1 Tumour-initiating ability of breast stem cells316 © 2009 The Authors
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Fig. 5  Breast tumour stem cells formed tumours in SCID mice and contributed to tumour vessel formation. (A) Representative micrographs of tumour
sections showing positivity for low-weight cytokeratins AE1/AE3 (CKAE1/3), EMA and vimentin, but not for CK5/6ER, EGF-R and c-Erb2. (Original
magnifications: 100). (B) Representative immunofluorescence micrographs showing co-localization of human HLA class I and human CD31
(hCD31) in vessels within the mammosphere-generated tumours, as seen by confocal microscopy (Original magnifications: 400). In contrast, the
co-localization of human HLA and mouse CD31 (mCD31) in several vessels around and within the implanted tumour was absent (Original magnifica-
tions: 250). Data are representative of six experiments with similar results.J. Cell. Mol. Med. Vol 13, No 2, 2009
317 © 2009 The Authors
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Fig. 7 Vessels and tumour formation by endothelial differentiated
tumour stem cell clones subcutaneously injected in SCID mice. (A)
Representative micrograph showing the organization of endothelial dif-
ferentiated breast tumour stem cells injected subcutaneously in Matrigel
after 7 days. Several vessels connected with the mouse vasculature and
containing erythrocytes were observed (arrows). (B) Representative
micrograph of electron microscopy of vessels formed within Matrigel by
endothelial differentiated breast tumour progenitor cells injected subcu-
taneously in Matrigel after 7 days. The inset shows the immunofluores-
cence staining of vessels for human HLA Class I. (C) Representative
micrograph showing the formation of an epithelial tumour by the
endothelial differentiated breast tumour progenitor cells injected subcu-
taneously in Matrigel after 3 weeks. (Original magnifications: Panel A
and C 250; panel B 6000; inset, 400). Data are representative of
eight different tumors.
vimentin and EMA (not shown), thus resembling the tumour orig-
inated by mammospheres.
The ability of endothelial differentiated clones to generate epithe-
lial tumours in vivo may suggest that in the endothelial differentiated
breast cancer stem cells a non-differentiated population is main-
tained and it is able to differentiate into tumour epithelial cells in vivo.
Discussion
In the present study, we demonstrate that stem/progenitor cells of
breast carcinomas cultured as mammospheres could differentiate
not only in epithelial cells but also into endothelial cells both in vitro
and in vivo.
A tumour-initiating population able to sustain and maintain the
tumour has been identified in several organs [1]. The ability to
growth in suspension, as floating spheres has been described as a
culture system that allows the propagation of normal and tumour
mammary stem cells in an undifferentiated state [16].
In the present paper, we used a population of breast tumour
stem cells, cultured as mammospheres. Breast tumour stem
cells expressed the stem markers nestin and Oct-4 and were
negative for epithelial and endothelial differentiation markers.
Mammospheres could be cultured in vitro for more then 50 pas-
sages and showed enhanced tumourigenesis in respect to differ-
entiated cells. Clonal mammospheres were obtained by plating
one single cell raising secondary mammosphere clones.
Secondary mammospheres were submitted to subsequent
cloning, generating long-term tertiary mammosphere clones.
Fig. 6 Origin of vessels present in breast tumour stem cells formed
tumours. (A) Immunohistochemistry for human HLA class I antigen
showed the positivity of human endothelial cells within tumour
(arrows) and of tumour cells. In the inset, human HLA class I antigen
is detected by immunofluorescence (the arrow indicates a positive ves-
sel). (B) Immunohistochemistry for mouse 	2 microglobulin showed
the presence of murine vessels and isolated cells at the periphery of the
tumour (inset). (Original magnifications: 250). (C) FISH analysis for
chromosome 17 followed by immunofluorescence analysis for human
CD31 Ab showed the co-expression by endothelial cells of the human
chromosome 17 (arrows). (Original magnification: 650). Data are
representative of six experiments with similar results.318 © 2009 The Authors
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These results show the self-renewal and the tumour-initiating
ability of this cell population comparable to that described by
Ponti et al. [6].
Tumour-initiating cells or ‘cancer stem cells’ are character-
ized by their ability to display stem/progenitor cell properties:
competence for self-renewal and capacity to differentiate in a
heterogeneous tumour cell population [1, 2]. In addition, if the
notion that tumour stem cells originate from mutated stem cells
of the tissue is true, it is conceivable that tumour stem cells may
differentiate in different lineages. This has been shown for
melanoma-derived stem cells that are able to differentiate in mul-
tiple mesenchymal lineages such as adypocitic, osteocytic and
chondrocytic lineages [17]. Breast tumour stem cells have been
reported to differentiate in the epithelial linage but a cross-lineage
potential has not been investigated.
In the present study, we demonstrated that breast tumour
stem cells are able to differentiate also into endothelial cells.
Undifferentiated breast tumour stem cells expressed the VEGF
receptor 1, but not VEGF receptor 2 or 3, suggesting that VEGF-
induced endothelial differentiation may depend, at least in the
first phase, on the engagement of this receptor known to trigger
endothelial differentiation of other stem cell types [18]. This was
shown by the acquirement of endothelial markers and proper-
ties, such as the ability to organize in Matrigel into capillary-like
structures, by differentiated cells. Several studies have suggest-
ed the possibility that tumour cells express endothelial markers.
In human tissue specimens of ductal in situ carcinomas, the
expression of CD31 has been shown in the epithelial cells [19].
Other studies supported the idea that melanoma cells may
acquire functional behaviours that are similar to those of
endothelial cells [20]. Aggressive melanoma cells that form
blood-carrying channels in tumours also exhibited capillary-like
structure formation and co-expressed epithelial and some
endothelial-like markers [9, 21, 22].
In the present study, the endothelial differentiation from stem
cells was not associated with the co-expression of epithelial mark-
ers. Moreover, stem cells once differentiated into epithelial cells
did not acquire endothelial markers when cultured in the endothe-
lial differentiation medium. These results suggest a differentiation
rather then a process of ‘vasculogenic mimicry’. Evidence of an in
vivo differentiation of stem cells into endothelial cells is provided
by the observation that at least a fraction of the vessels present in
the transplanted tumours, originated from mammospheres, were
of human origin.
The concept that at least some of the vessels present in
tumours may derive from the tumour stem cells indicate the con-
tribution of an intratumour vasculogenesis to the tumour vascu-
larization. Several reports indicate that endothelial cells within
tumours are different from normal endothelial cells [12, 23], are
cytogenetically abnormal [24] and express tumour suppressor
genes and oncogenes [23, 25]. In addition, in the case of tumours
of hematopoietic origin, endothelial cells were shown to share the
tumour-specific genetic alteration, such as chromosomal translo-
cations in B-cell lymphomas, the BCR/ABL fusion gene in
leukaemias and the myeloma-specific 13q14 chromosomal dele-
tion [26–28]. These data may suggest the hypothesis that a com-
mon progenitor targeted by neoplastic transformation can differ-
entiate in tumour cells or in endothelial cells sharing the same
genetic abnormalities [27]. Regarding solid tumours, it was
recently shown the endothelial cells present in neuroblastomas
presented the same genetic amplification of neuroblastoma cells
indicating that tumour endothelial cells may derive from tumour
cell [29]. Among the different explications, our data support the
hypothesis that a stem cell fraction of the tumour may be able to
differentiate both into tumour cells and into endothelial cells. In
this context, the tumour microenvironment may orchestrate their
differentiation.
In vivo, mammosphere-derived single cells cloned in endothe-
lial differentiating medium were able to induce both vessels and
tumour formation. This suggests that in the endothelial-differenti-
ated cells, a stem cell population is maintained and it is able in
vivo to originate the tumour. The maintenance of stem cells in a
differentiated cell population, achieved by asymmetrical division of
stem cells, has been reported in a number of cell lines in culture
[30, 31], including the mammary cell line MCF7 [6, 32]. In the
present experiments, a single stem cell cloned in endothelial dif-
ferentiating medium gave raise to about 90% cells expressing an
endothelial phenotype and a small percentage of undifferentiated
cells. It is therefore possible that the tumourigenic potential
retained by the endothelial-differentiated clones may depend on
these cells with stem/progenitor characteristics. However, we 
cannot definitely rule out the possibility that endothelial differenti-
ated cells may revert to an epithelial phenotype. The rapid forma-
tion of tumour cluster within Matrigel in vivo may suggest that
from a single stem cell of a single clone, a population of progeni-
tors with bipotent tumourigenic and vasculogenic differentiating
property is generated.
The ability of stem/progenitor cells to generate multiple lin-
eages is considered a hallmark of stemness. The results of the
present study demonstrate that tumour-initiating stem cells of
breast cancer have the ability to differentiate not only in
epithelial lineages but also in endothelial cells, further sup-
porting the hypothesis that the tumour-initiating population
possesses stem cell characteristics relevant for tumour
growth and vascularization.
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